Please login to the form below

Not currently logged in
Email:
Password:

Ipsen appoints executive vice president

Alexandre Lebeaut also set to be chief scientific officer

Alexandre_Lebeaut_IpsenIpsen has appointed Dr Alexandre Lebeaut as its new executive VP, research and development, and chief scientific officer to focus on the firm’s strategy to address unmet medical needs.

Lebeaut joined Ipsen in 2013 as senior VP, chief development officer, global drug development and was appointed interim head of R&D in December 2016.

Prior to joining Ipsen, Lebeaut has held several leadership positions in clinical development and medical affairs with biopharmaceutical companies including Axcan Pharmaceuticals, Sanofi and Novartis.

David Meek, CEO of Ipsen, said: “Dr Lebeaut has consistently demonstrated an unwavering commitment to innovation, collaboration and successful execution of drug development strategies.

“During his four years at Ipsen, Dr Lebeaut has been instrumental in successfully leading our global development programmes.

“He will continue to lead the transformation of Ipsen’s R&D strategy to further build a differentiated and sustainable portfolio to continue to address unmet medical needs in our key areas of expertise.”

18th April 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...
Digital technologies: Pharma’s answer to achieving net zero emissions?
...